Primaquine

Administration

  • Type: Anti-malarial, anti-PCP
  • Dosage Forms:
  • Routes of Administration: oral
  • Common Trade Names:

Adult Dosing

  • PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
  • Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
  • Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Pediatric Dosing

  • Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
  • Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Special Populations

Contraindications

  • Allergy to class/drug
  • Concomitant use with other potentially hemolytic or myeloid suppressing drugs
  • Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)

Adverse Reactions

Serious

  • Hemolytic anemia, leukopenia
  • Methemoglobinemia

Common

  • Nausea, abdominal pain

Pharmacology

  • Half-life: 4-7 hours
  • Metabolism:
  • Excretion:

Mechanism of Action

  • Eliminates tissue infection, thus preventing erythrocytic forms of parasite

Comments

See Also

References